减瘤性肾切除术后生存预测模型的验证比较
该研究在2005-2017年单中心515例接受减瘤性肾切除术的转移性肾细胞癌患者中验证10种预后模型的判别能力。全部模型c-index均低于原始发表值,范围0.53-0.61,MSKCC和IMDC模型分别为0.55和0.56。现有模型判别能力有限,不足以用于风险分层和临床试验随机化。
要点
- 10种预后模型在减瘤性肾切除人群中判别能力均低于原始发表值
- c-index范围0.53-0.61,Leibovich模型最高,Cindolo模型最低
- MSKCC和IMDC模型c-index分别为0.55和0.56,判别能力差
核心结论
- 现有预后模型在减瘤性肾切除患者中判别能力有限,不足以用于风险分层和前瞻性临床试验随机化。
- 临床决策中使用这些模型需谨慎。
研究设计与样本
- 单中心回顾性验证研究,纳入2005-2017年接受减瘤性肾切除术的515例转移性肾细胞癌患者。
- 选择10种临床相关预后模型进行验证,计算c-index并与原始发表值比较。
主要发现
- 515例患者中387例(75%)在研究期间死亡,估计3年生存率46.1%(95%CI 41.6-50.4%)。
- 所有模型判别能力均低于原始发表c-index。
- c-index范围从Cindolo模型的0.53(95%CI 0.50-0.56)到Leibovich模型的0.61(95%CI 0.58-0.64)。
- MSKCC和IMDC模型c-index分别为0.55和0.56。
临床怎么用
- 不应依赖这些模型对减瘤性肾切除患者进行风险分层或临床试验随机化。
- 用于临床决策时需谨慎,避免仅凭模型评分做出治疗选择。
局限性
- 单中心回顾性研究,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To validate models currently used to predict metastatic renal cell carcinoma (mRCC) outcomes in a cohort of patients undergoing cytoreductive nephrectomy (CN). PATIENTS AND METHODS: A total of 10 RCC prognostic models (International Metastatic RCC Database Consortium [IMDC]; Memorial Sloan Kettering Cancer Center [MSKCC]; Culp; Leibovich; University of California at Los Angeles Integrated Staging System [UISS]; Stage, Size, Grade, and Necrosis [SSIGN]; Yaycioglu; Karakiewicz; Cindolo; and Margulis) were chosen based on clinical relevance and use in clinical trial design. Model validation was performed using patients who underwent CN at a single institution between 2005 and 2017, and model discrimination (ability to select patients at risk of death) was assessed. Concordance indices (c-index) were calculated and compared with originally published c-indices. RESULTS: A total of 515 CN patients were stratified according to the prognostic models. A total of 387 (75%) died over the study period, with estimated 3-year survival of 46.1% (95% confidence interval [CI] 41.6-50.4%). All models' discriminatory capacity underperformed when compared to the originally published c-indices. The c-indices ranged from 0.53 (95% CI 0.50-0.56) for the Cindolo model to 0.61 (95% CI 0.58-0.64) for the Leibovich model. The MSKCC and IMDC models performed poorly with c-indices of 0.55 and 0.56, respectively. CONCLUSION: Currently used prognostic models have limited discriminatory capacity when applied to a modern cohort of patients undergoing CN. They are inadequate for risk stratification and randomisation in prospective clinical trials of untreated patients with mRCC. Caution should be used when using these models for clinical decision making.
引用
- Westerman ME, Shapiro DD, Tannir NM, et al. Survival following cytoreductive nephrectomy: a comparison of existing prognostic models. BJU Int. 2020. PMID: 32623821. doi:10.1111/bju.15160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。